Browsing Tag
COMPASS Pathways
3 posts
Compass Pathways fast-tracks COMP360 launch timeline as Q3 2025 results show improved financial runway
Learn how Compass Pathways’ faster COMP360 launch timeline after Q3 2025 results could reshape the psychedelics industry and investor sentiment.
Who’s funding the psychedelic revolution in pharma? Follow the money from PIPEs to Big Pharma M&A
Psychedelic biotech is evolving—from VC hype to pharma buyouts. Discover who’s funding the next generation of depression treatments in 2025.
Can short-acting psychedelics solve the scalability problem in depression treatment?
Short-acting psychedelics like bretisilocin could reshape mental health treatment. Can they overcome the clinical bottlenecks faced by psilocybin and ketamine?